↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

111 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
2 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
4 African trypanosomiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
5 African trypanosomiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
9 Allograft rejection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
10 Allograft rejection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
11 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
12 Alzheimer disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
13 Alzheimer disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
14 Amoebiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
15 Amoebiasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
16 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
17 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
18 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
19 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
20 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
21 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
22 Antifolate resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
23 Antifolate resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
24 Antigen processing and presentation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
25 Antigen processing and presentation 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
26 Apoptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
27 Apoptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
28 Asthma 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
29 Asthma 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
30 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
31 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
32 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
33 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
34 Biosynthesis of cofactors 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 💬
35 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
36 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
37 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
38 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
39 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
40 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
41 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
42 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
43 Chagas disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
44 Chagas disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
45 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
46 Cholinergic synapse 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
47 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
48 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
49 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
50 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
51 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
52 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
53 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
54 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
55 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
56 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
57 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
58 DNA replication 💬
 2件: POLA1, POLA2 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
59 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
60 Drug metabolism - other enzymes 💬
 1件: RRM1 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
61 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
62 EGFR tyrosine kinase inhibitor resistance 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
63 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
64 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
65 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
66 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
67 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
68 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
69 Estrogen signaling pathway 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
70 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
71 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
72 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
73 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
74 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
75 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
76 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
77 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
78 Glutathione metabolism 💬
 1件: RRM1 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
79 Graft-versus-host disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
80 Graft-versus-host disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
81 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
82 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
83 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
84 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
85 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
86 Hepatitis B 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
87 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
88 Hepatitis B 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
89 Hepatitis B 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
90 Hepatitis C 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
91 Hepatitis C 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
92 Hepatitis C 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
93 Hepatitis C 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
94 Herpes simplex virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
95 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
96 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
97 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
98 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
99 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
100 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
101 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
102 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
103 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
104 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
105 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
106 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
107 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
108 Human papillomavirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
109 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
110 Human papillomavirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
111 Human papillomavirus infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
112 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
113 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
114 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
115 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
116 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
117 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
118 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
119 IL-17 signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
120 IL-17 signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
121 Inflammatory bowel disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
122 Inflammatory bowel disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
123 Influenza A 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
124 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
125 Influenza A 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
126 Influenza A 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
127 Insulin resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
128 Insulin resistance 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
129 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
130 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
131 JAK-STAT signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
132 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
133 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
134 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
135 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
136 Legionellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
137 Legionellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
138 Leishmaniasis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
139 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
140 Leishmaniasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
141 Leishmaniasis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
142 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
143 Malaria 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
144 Malaria 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
145 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
146 MAPK signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
147 MAPK signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
148 Measles 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
149 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
150 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
151 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
152 Metabolic pathways 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 💬
153 Metabolic pathways 💬
 1件: RRM1 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
154 Morphine addiction 💬
 1件: OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
155 Morphine addiction 💬
 1件: OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
156 mTOR signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
157 mTOR signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
158 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
159 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
160 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
161 Necroptosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
162 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
163 Necroptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
164 Necroptosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
165 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00407 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
166 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00751 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
167 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00979 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
168 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05000 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
169 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05001 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
170 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D05002 💬 Methylprednisolone 44件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
171 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00472 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
172 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00980 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
173 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00981 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
174 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00982 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
175 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01239 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
176 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D01998 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
177 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D02156 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
178 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D03301 💬 Prednisolone 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
179 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 47件:  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
180 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D08416 💬 Prednisone acetate 6件: 35, 40, 41, 49, 162, 224 💬
181 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
182 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
183 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
184 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
185 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
186 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
187 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
188 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
189 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
190 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
191 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
192 Non-small cell lung cancer 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
193 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
194 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
195 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
196 Osteoclast differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
197 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
198 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
199 Osteoclast differentiation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
200 Osteoclast differentiation 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
201 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
202 Pancreatic cancer 💬
 1件: JAK1 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
203 Pancreatic cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
204 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
205 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
206 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
207 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
208 Pathways in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
209 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
210 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
211 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
212 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
213 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
214 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
215 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
216 Pertussis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
217 Pertussis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
218 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
219 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
220 PI3K-Akt signaling pathway 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
221 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
222 Primary immunodeficiency 💬
 1件: JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
223 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
224 Prion disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
225 Prion disease 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
226 Prolactin signaling pathway 💬
 1件: JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
227 Proteoglycans in cancer 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
228 Proteoglycans in cancer 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
229 Purine metabolism 💬
 1件: RRM1 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
230 Pyrimidine metabolism 💬
 1件: DHODH 💬 D00749 💬 Leflunomide 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 💬
231 Pyrimidine metabolism 💬
 1件: RRM1 💬 D03546 💬 Clofarabine 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬
232 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
233 Rheumatoid arthritis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
234 Rheumatoid arthritis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
235 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
236 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
237 Salmonella infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
238 Salmonella infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
239 Shigellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
240 Shigellosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
241 Signaling pathways regulating pluripotency of stem cells 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
242 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
243 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D02095 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
244 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 D05113 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
245 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
246 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
247 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
248 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
249 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
250 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
251 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
252 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
253 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
254 Th1 and Th2 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
255 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
256 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
257 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
258 Th17 cell differentiation 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
259 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
260 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
261 TNF signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
262 TNF signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
263 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
264 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
265 Toxoplasmosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
266 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
267 Toxoplasmosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
268 Toxoplasmosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
269 Tuberculosis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
270 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
271 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
272 Tuberculosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
273 Tuberculosis 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
274 Type I diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
275 Type I diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
276 Type II diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
277 Type II diabetes mellitus 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
278 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
279 Viral carcinogenesis 💬
 1件: JAK1 💬 D10994 💬 Upadacitinib 7件: 40, 41, 46, 49, 96, 97, 271 💬
280 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 D09970 💬 Tofacitinib 12件: 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬
281 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
282 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
283 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
284 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00184 💬 Cyclosporine 43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
285 Yersinia infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
286 Yersinia infection 💬
 1件: TNF 💬 D02598 💬 Infliximab 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬

先頭へ